- PCB39: Statement of Knowledge Ecology International on Agenda item 6: UNAIDS synthesis report on IP
- UNAIDS PCB 39: Statement of India on the Executive Director's Report to the 39th PCB
- EB140: World Health Organization publishes annotated agenda for January 2017 Executive Board
- SCCR33: Conclusions - Protection of Broadcasting Organizations
- SCCR33: Conclusions - Artist Resale Right (droit de suite)
- SCCR33: Conclusions - Proposal for Analysis of Copyright Related to the Digital Environment
- SCCR 33, KEI's intervention on legal protection for technological protection measures
- SCCR33 - Statement by the Latin American and Caribbean Group (GRULAC) - Limitations on liability for libraries and archives
- SCCR 33: NGOs Statements on Casting treaty in Plenary November 16, 2016
- SCCR 33: Notes from KEI NGO statement on WIPO broadcast treaty negotiations, November 16, 2016
April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patentsSubmitted by KEI Staff on 12. May 2016 - 10:25
Update: english translation of letter now available at end this blog.
KEI Statement SCCR 32 Day 4 on "Orphan works" and Libraries and Archives
I will be speaking here as a user of libraries and archives and as a user of out of print and orphan works for my past academic work and my research today.
April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory licenseSubmitted by KEI Staff on 11. May 2016 - 7:20
Senator Hatch, before pressuring Colombia over cancer drug compulsory license, wanted one for NapsterSubmitted by Andrew Goldman on 10. May 2016 - 15:17
(More on Colombia here: http://keionline.org/colombia)
Good afternoon, and thank you very much, sir.
I wanted to refer to the rights to be granted in this proposed treaty and I would like to give you an example of something that has recently happened in Colombia and how sometimes the retransmission rights can be abused.
Today the Department of Health and Human Services held their annual WHA listening session. This year HHS sent an email the day prior announcing that the usual 3 minute allotment would be cut in half to 90 seconds. This decision caused several NGOs to not attend.
2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds
More on NIH licensing at http://keionline.org/nih-licenses
May 4, 2016
Betty Tong, Ph.D.
Senior Licensing and Patenting Manager
Technology Advancement Office
National Institute of Diabetes and Digestive and Kidney Diseases
12A South Drive,
Bethesda, MD 20892
Via email: email@example.com
May 4, 2016
Dear Dr. Betty Tong,
Astellas has claimed that patients taking Xtandi face very small co-payments. One patient living in Arizona contacted KEI with proof that Astellas' claims just aren't true. The patient, who is on Medicare, provided a copy of a summary of his expenses for the first quarter of of 2016.
His monthly patient co-payment is $441.97 a month.
2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technologySubmitted by Zack Struver on 3. May 2016 - 13:46
Other KEI comments on NIH licenses are found here: http://keionline.org/nih-licenses
In response to a February request under the Freedom of Information Act (FOIA) for documents related to the grant of an exclusive patent license on a HER2+ breast cancer treatment technology, the National Institutes of Health (NIH) withheld in full all responsive records.
WHO CEWG 2016: Statement of Health Action International, Knowledge Ecology International and STOPAIDSSubmitted by thiru on 2. May 2016 - 4:09
On Monday, 2 May 2016, the World Health Organization (WHO) convened the 2016 open-ended member states meeting of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). The 2016 CEWG is chaired by Bhanu Pratap Sharma, Secretary, Ministry of Health and Family Welfare, Government of India. The Vice-Chair is Tania Dussey- Cavassini, Vice-Director General, Ambassador for Global Health, Federal Office of Public Health, Switzerland.
Rep. Lloyd Doggett keynote address at CAP drug pricing event highlights Xtandi, federal funding of pharmaceutical R&DSubmitted by Zack Struver on 29. April 2016 - 13:46
On April 26, 2016, Congressman Lloyd Doggett (D-Texas) delivered the keynote address at a panel discussion on drug pricing at the Center for American Progress, where he addressed the Federal government’s role in subsidizing drug development, ensuring affordable access at reasonable prices for U.S. citizens, industry practices related to monopoly pricing, and legislative solutions to promote rational and affordable drug prices.
The number of patents filed by China has accelerated over the last 15 years. According to WIPO, China represented just 1 percent of the fillings with the PCT in 2000. By 2015, China's share of PCT filing was 13.7 percent. We were interested to see how this increase in patent fillings related to China's growth in GDP.
Biolyse Pharma offers to supply enzalutamide (Xtandi) for $3 per pill to Medicare and developing countriesSubmitted by Zack Struver on 27. April 2016 - 14:03
On April 22, 2016, the President of Biolyse Pharma — a Canadian pharmaceutical company that specializes in the manufacture of oncology drugs — offered to supply the prostate cancer drug enzalutamide (Xtandi) to the Centers for Medicare & Medicaid Services (CMS) for $3 per pill ($12 per day; $4,383 per year). The Biolyse price for enzalutamide is 4-percent of the 2014 Medicare price, $69.41 ($277.64 per day; $101,408.01 per year), and lower than any other price in the world.
The 2016 USTR Special 301 report is now available. (copy here). The report is 77 pages of complaints about intellectual property policies around the world, plus a number of other complaints, including those related to pricing and reimbursement of pharmaceutical drugs and medical devices, restrictions on data flows, standard setting, and government procurement.
On the one hand, USTR says it is supports "access to medicine for all."